Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33.95% | -43.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.41% | -35.49% | |||
| Operating Income | 24.41% | 35.49% | |||
| Income Before Tax | 105.48% | 404.64% | |||
| Income Tax Expenses | 110.52% | 5,350.00% | |||
| Earnings from Continuing Operations | 104.01% | 282.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 104.01% | 282.76% | |||
| EBIT | 24.41% | 35.49% | |||
| EBITDA | 24.63% | 35.68% | |||
| EPS Basic | 102.68% | 317.79% | |||
| Normalized Basic EPS | -143.29% | 180.16% | |||
| EPS Diluted | 102.20% | 304.62% | |||
| Normalized Diluted EPS | -143.16% | 177.83% | |||
| Average Basic Shares Outstanding | 0.65% | -0.32% | |||
| Average Diluted Shares Outstanding | 1.27% | 2.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -1.00% | -- | |||